| Market Cap | 3.01B | P/E | - | EPS this Y | -16.10% | Ern Qtrly Grth | - |
| Income | -17.37M | Forward P/E | 288.44 | EPS next Y | 103.80% | 50D Avg Chg | 2.00% |
| Sales | 641.02M | PEG | 16.32 | EPS past 5Y | -22.13% | 200D Avg Chg | -4.00% |
| Dividend | N/A | Price/Book | 1.10 | EPS next 5Y | 12.00% | 52W High Chg | -35.00% |
| Recommedations | 2.70 | Quick Ratio | 4.98 | Shares Outstanding | 55.77M | 52W Low Chg | 28.00% |
| Insider Own | 1.90% | ROA | -1.47% | Shares Float | 49.84M | Beta | 1.49 |
| Inst Own | 104.45% | ROE | -0.65% | Shares Shorted/Prior | 4.16M/4.11M | Price | 46.15 |
| Gross Margin | 40.63% | Profit Margin | -2.92% | Avg. Volume | 1,114,354 | Target Price | 69.60 |
| Oper. Margin | -16.56% | Earnings Date | May 7 | Volume | 664,628 | Change | 0.07% |
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
| Needham | Buy | Apr 8, 24 |
| Evercore ISI Group | In-Line | Apr 4, 24 |
| Jefferies | Hold | Apr 4, 24 |
| Needham | Buy | Mar 28, 24 |
| Needham | Buy | Mar 14, 24 |
| Needham | Buy | Mar 7, 24 |
| Stephens & Co. | Equal-Weight | Feb 8, 24 |
| Needham | Buy | Feb 8, 24 |
| B. Riley Securities | Buy | Feb 1, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Robertson Lindon G | EVP & Chief Financia.. EVP & Chief Financial Officer | Aug 19 | Buy | 57.62 | 4,350 | 250,647 | 100,571 | 08/22/22 |
| McManus Matthew | EVP & Chief Operatin.. EVP & Chief Operating Officer | Aug 19 | Buy | 58.15 | 8,625 | 501,544 | 29,467 | 08/22/22 |
| Crowley Kimberly | SVP, Chief HR Office.. SVP, Chief HR Officer | Apr 12 | Sell | 78.02 | 132 | 10,299 | 5,133 | 06/07/22 |
| Vacha Robin | SVP, GM BLS-Products SVP, GM BLS-Products | Nov 20 | Sell | 69.62 | 6,490 | 451,834 | 18,575 | 11/20/20 |
| SCHWARTZ STEPHEN S | CEO CEO | Nov 20 | Sell | 69.62 | 27,822 | 1,936,968 | 377,711 | 11/20/20 |
| Robertson Lindon G | EVP & Chief Financia.. EVP & Chief Financial Officer | Nov 20 | Sell | 69.62 | 13,983 | 973,496 | 77,266 | 11/20/20 |
| Joseph Jason | SVP, General Counsel.. SVP, General Counsel, Secy. | Nov 20 | Sell | 69.62 | 5,925 | 412,498 | 85,855 | 11/20/20 |
| SCHWARTZ STEPHEN S | CEO CEO | Sep 17 | Sell | 45.17 | 69,291 | 3,129,874 | 346,043 | 09/17/20 |
| SCHWARTZ STEPHEN S | CEO CEO | Sep 11 | Sell | 45.08 | 33,910 | 1,528,663 | 415,334 | 09/11/20 |